MolecularMD Closes $6 Million Series B Financing and Announces Ensuing Growth Initiatives PORTLAND, OR--(Marketwire - Apr 2, 2012) - MolecularMD Corp. announces that it has closed a $6 Million Series B equity financing led by existing investor, Ballast Point Ventures, which is joined by...

MolecularMD Announces Issuance of Patent Covering Methods for Therapeutic Resistance Monitoring in Lung Cancer Patients PORTLAND, OR--(Marketwire - Dec 9, 2011) - MolecularMD Corp. today announces the issuance of a patent titled "Methods and Compositions for Detecting a Drug Resistant EGFR Mutant." The newly issued...

MolecularMD Corp. Obtains Exclusive License From NYU and MSKCC for BRAF Melanoma Assay PORTLAND, OR--(Marketwire - October 18, 2010) - MolecularMD Corp. announced today that it has entered into a licensing agreement with New York University (NYU) and Memorial Sloan-Kettering Cancer...

MolecularMD Establishes New Operations Facility to Support Growth in Personalized Cancer Medicine Business PORTLAND, OR--(Marketwire - October 28, 2009) - MolecularMD Corp announced today that it has moved their core operations to a expanded dedicated facility with capacity and functionality to support...